Pharmaceutical

Amylyx considers scrapping ALS drug following Phase III flop

Amylyx’s stocks plummeted by more than 85% after announcing it is considering scrapping the drug due to the trial failure.

Mar 9, 2024 - 18:00
Amylyx considers scrapping ALS drug following Phase III flop
Amylyx’s stocks plummeted by more than 85% after announcing it is considering scrapping the drug due to the trial failure.
Read the original article

Tags:

Previous Article

AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine  

Next Article

Oligonucleotides: Overcoming sustainability challenges with manufacturing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CMN-005 by CoImmune for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CMN-005 by CoImmune for Relapsed Chronic Lymphocytic Le...

Sep 10, 2024

STAT+: Biden administration goes easy on Medicare Advantage insurers after intense industry lobbying

STAT+: Biden administration goes easy on Medicare Advan...

Apr 1, 2023

Opinion: Sanofi CEO Paul Hudson: The right way to bring AI into pharma

Opinion: Sanofi CEO Paul Hudson: The right way to bring...

Sep 8, 2023